Aurora A Antibody [Unconjugated]

Western blot shows lysates of HeLa human cervical epithelial carcinoma cell line. PVDF membrane was probed with 0.25 µg/mL of Human Aurora A Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3295) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for Aurora A at approximately 54 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 5.

Simple Western lane view shows lysates of HeLa human cervical epithelial carcinoma cell line, loaded at 0.2 mg/mL. A specific band was detected for Aurora A at approximately 56 kDa (as indicated) using 12.5 µg/mL of Goat Anti-Human Aurora A Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3295) followed by 1:50 dilution of HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

• Reactivity: Hu
• Applications: WB, Simple Western
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

Aurora A Antibody [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant human Aurora A
  Met1-Glu131
  Accession # O14965
• Specificity: Detects human Aurora A in Western blots.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: AURKA
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Western Blot 0.25 ug/mL
  • Simple Western 12.5 ug/mL
• Application Notes: In Simple Western only 10-15 uL of the recommended dilution is used per data point.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Purity: Immunogen affinity purified
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Aurora A Antibody [Unconjugated]

• AIK
• AIKAurA
• ARK1
• ARK-1
• ARK1EC 2.7.11.1
• AURA
• AURKA
• Aurora A
• aurora kinase AhARK1
• aurora/IPL1-like kinase
• Aurora/IPL1-related kinase 1
• Aurora-related kinase 1
• Breast tumor-amplified kinase
• breast-tumor-amplified kinase
• BTAK
• BTAKAURORA2
• EC 2.7.11
• IPL1-related kinase
• serine/threonine kinase 6
• serine/threonine protein kinase 15
• Serine/threonine-protein kinase 15
• serine/threonine-protein kinase 6
• Serine/threonine-protein kinase aurora-A
• STK15
• STK15serine/threonine kinase 15
• STK6
• STK6MGC34538
• STK7

Background

Aurora A is a serine/threonine kinase that regulates chromosome segregation and cytokinesis during mitosis. Its kinase activity is thought to regulate the G₂ to M transition of the cell cycle by phosphorylating BRCA1. Aberrant expression and activity of Aurora A in tumors, including breast, ovarian, gastric and colorectal cancer, suggests that it plays a role in tumor development and progression.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Aurora A Antibody (AF3295)(3)

Publications using AF3295

• J Du, L Yan, R Torres, X Gong, H Bian, C Marugán, K Boehnke, C Baquero, YH Hui, SC Chapman, Y Yang, Y Zeng, SM Bogner, RT Foreman, A Capen, GP Donoho, RD Van Horn, DS Barnard, JA Dempsey, RP Beckmann, MS Marshall, LC Chio, Y Qian, YW Webster, A Aggarwal, S Chu, S Bhattachar, LF Stancato, MS Dowless, PW Iversen, JR Manro, JL Walgren, BW Halstead, MZ Dieter, R Martinez, SV Bhagwat, EL Kreklau, MJ Lallena, XS Ye, BKR Patel, C Reinhard, GD Plowman, DA Barda, JR Henry, SG Buchanan, RM Campbell Aurora A selective inhibitor LY3295668 leads to dominant mitotic arrest, apoptosis in cancer cells and shows potent preclinical antitumor efficacy Mol. Cancer Ther., 2019;0(0):. 2019 [PMID: 31530649] (ICC, Human)
• X Gong, J Du, SH Parsons, FF Merzoug, Y Webster, PW Iversen, LC Chio, RD Van Horn, X Lin, W Blosser, B Han, S Jin, S Yao, H Bian, C Ficklin, L Fan, A Kapoor, S Antonysamy, AM Mc Nulty, K Froning, D Manglicmot, A Pustilnik, K Weichert, SR Wasserman, M Dowless, C Marugán, C Baquero, MJ Lallena, SW Eastman, YH Hui, MZ Dieter, T Doman, S Chu, HR Qian, XS Ye, DA Barda, GD Plowman, C Reinhard, RM Campbell, JR Henry, SG Buchanan Aurora-A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene Cancer Discov, 2018;0(0):. 2018 [PMID: 30373917] (Western Blot, Human)
• Tiedemann RE, Zhu YX, Schmidt J, Yin H, Shi CX, Que Q, Basu G, Azorsa D, Perkins LM, Braggio E, Fonseca R, Bergsagel PL, Mousses S, Stewart AK Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood, 2010;115(8):1594-604. 2010 [PMID: 19996089] (Western Blot, Human)

Bioinformatics

• Gene Symbol: AURKA
• Uniprot:
  • O14965()